How do we communicate the potential of a new class of drugs to investors and partners?
During our two periods of supporting Ablynx’s communications (prior to and during IPO and SPO, and more recently) our brief was to provide strategic communications counsel, finesse messaging and to ensure that International media relations supported fair valuation. Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments.
Having supported Ablynx with corporate and financial communications and its early preparations for and listing on Euronext, we assisted with the drafting and production of key investor materials. We also executed an international media relations programme. More recently we have developed a communications strategy to develop a greater social media presence and actively provided communications around the Company’s significant focus on immuno-oncology, as well as communicating clinical pipeline advances.
Ablynx IPO and SPO were successful and professionally executed, with on-message media coverage. Today the Company is widely recognised as one of the most successful European biotechs having taken its technology through from the lab to the development of a substantial in-house pipeline of therapeutics and many impressive pharma partnerships.
It is destined to be one of the few European listed biotechs to pass the $1b market cap.